Highly Potent Active Pharmaceutical Ingredients 2017 Conference

The global market for Highly Potent Active Pharmaceutical Ingredients is currently on a growth fast track, largely driven by its major use in oncology for cancer treatment and more often in the form of ADCs. Over a quarter of drugs worldwide now contain HPAPIs, as they have proven to be more effective than other APIs. However, working with APIs high in potency and cytotoxicity comes with many regulations and requirements, and presents pharmaceutical companies with challenges such as handling, containment, cost and security questions.

The inaugural Highly Potent Active Pharmaceutical Ingredients conference features key speakers of the industry presenting challenges, issues, innovation and new developments in various areas of HPAPI production, development and manufacturing.

Hear about new innovative containment risk assessment tools and containment strategies when handling HPAPI products. Guidance for the evaluation and management of cross-contamination will be addressed, as well as newest control strategies and solutions.

Pharmaceutical companies will be presenting their approaches to scale-up processes and will be discussing manufacturing facility designs and requirements, also introducing flexible facilities. Learn more about CMO selection strategies and how to improve information and technology transfer.

This conference will cover many important and in-demand aspects of the HPAPI industry, creating a networking platform for industry professionals and key players to share their knowledge and find innovative new solutions.

Benefits of Attending

• Learn how to reduce HPAPI manufacturing costs and get the best value for your money without cutting back on the importance of safety and containment procedures.
• Network with industry fellows and hear about new developments, innovation and challenges in areas such as cross-contamination, manufacturing efficiency, safety practices, outsourcing strategies, compound development and manufacturing, etc.
• Hear about the HPAPI market development, reasons why it's growing so rapidly and how to benefit from this, as well as why the HPAPI demand is still higher than the supply despite there being various suppliers involved in the industry.
• Experience an information-packed learning environment, designed to provide you with the best insight into new innovation in the HPAPI sector, leaving you well prepared for the challenges you're currently facing.

Plus Two Interactive Half-Day Post-Conference Workshops | Wednesday 24th May 2017

A: Preventing Cross Contamination & Employee Exposures
in the context of HPAPIs
Workshop Leader: Dean Calhoun, President / CEO, Affygility Solutions
08.30 - 12.30

B: Risk assessment in HPAPIs (HAZOP)
Workshop Leader: Yaakov Machlav, Process Safety Manager, Teva Pharmaceuticals
13.30 - 17.30